FindTrial
Sign In

RO6870810

DRUG5 trials

Sponsors

Hoffmann-La Roche

Conditions

Acute Myeloid LeukemiaAdvanced Ovarian CancerDiffuse Large B-cell LymphomaHigh-Grade B-cell LymphomaMultiple MyelomaMyelodysplastic SyndromesSolid Tumors, Advanced Solid TumorsTriple Negative Breast Cancer

Phase 1

A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies
CompletedNCT01987362
Hoffmann-La RocheSolid Tumors, Advanced Solid Tumors
Start: 2013-10-16End: 2017-10-11Updated: 2018-01-05
A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome
CompletedNCT02308761
Hoffmann-La RocheAcute Myeloid Leukemia, Myelodysplastic Syndromes
Start: 2014-11-06End: 2017-08-09Updated: 2017-12-11
Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma
CompletedNCT03068351
Hoffmann-La RocheMultiple Myeloma
Start: 2017-06-26End: 2019-08-01Updated: 2020-02-07
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
CompletedNCT03255096
Hoffmann-La RocheDiffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
Start: 2017-08-28End: 2019-07-03Updated: 2022-01-24
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
TerminatedNCT03292172
Hoffmann-La RocheAdvanced Ovarian Cancer, Triple Negative Breast Cancer
Start: 2017-11-08End: 2019-02-26Updated: 2020-11-06

Related Papers

Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).
2025-03-185 citations
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
Blood Advances2021-09-2836 citations
Abstract LB104: Dose-Finding/Expansion Phase Ib Study to Evaluate the Safety and Activity of BET Inhibitor RO6870810 (RO) and Atezolizumab (A) in Patients (pts) with Advanced Ovarian Cancer (OC) or Triple Negative Breast Cancer (TNBC)
Cancer Research2021-07-012 citations
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome
Leukemia & lymphoma/Leukemia and lymphoma2021-02-1335 citations
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
2020-12-1493 citations
Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma
Blood2020-11-055 citations
BET INHIBITOR RG6146, VENETOCLAX, AND RITUXIMAB IS A HIGHLY ACTIVE REGIMEN IN RELAPSED/REFRACTORY (R/R) DLBCL: INITIAL REPORT OF PHASE 1B SAFETY, BIOMARKER, AND RESPONSE DATA
Hematological Oncology2019-06-011 citations
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
Oncotarget2016-12-0792 citations